PTR 709 A

Drug Profile

PTR 709 A

Alternative Names: PTR 709

Latest Information Update: 03 May 2004

Price : $50

At a glance

  • Originator Peptor
  • Class
  • Mechanism of Action Peptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Atherosclerosis

Most Recent Events

  • 03 May 2004 Suspended - Preclinical for Atherosclerosis in USA (unspecified route)
  • 14 Jul 2003 Profile updated with data presented at the 10th Annual Meeting of the Biotechnology Industry Organization (BIO-2003)
  • 12 May 2003 Data from the BioSquare 2003 conference has been added as this compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top